# Study of Temzolomide and Gleevec in Advanced Melanoma

> **NCT00667953** · PHASE1,PHASE2 · TERMINATED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 32 (actual)

## Conditions studied

- Melanoma
- Advanced Melanoma

## Interventions

- **DRUG:** Gleevec
- **DRUG:** Temodar

## Key facts

- **NCT ID:** NCT00667953
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-01
- **Primary completion:** 2011-03-09
- **Final completion:** 2011-03-09
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Difficulty enrolling subjects
- **Last updated:** 2023-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00667953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00667953, "Study of Temzolomide and Gleevec in Advanced Melanoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00667953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*